Nirmatrelvir/Ritonavir

Tier C — Watch / trade

Pfizer Inc.

Originator

2022

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：3CLp, HIV-1 protease

Brand：Paxlovid

Indications (approved)：COVID-19

Regional status

Approved

2023-05-25

Approved

2022-01-28

China

Approved

2022-02-11

Japan

Approved

2022-02-10

Factories producing this API9

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

9 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Nirmatrelvir/Ritonavir?

Approved indications include: COVID-19.

When does the Nirmatrelvir/Ritonavir patent expire?

No public expiry year is available for Nirmatrelvir/Ritonavir yet; this page updates once verified.

How do I get a quote for Nirmatrelvir/Ritonavir intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27